GRO Biosciences raises seed funding | October 2, 2017 Issue - Vol. 95 Issue 39 | Chemical & Engineering News
Volume 95 Issue 39 | p. 15 | Concentrates
Issue Date: October 2, 2017

GRO Biosciences raises seed funding

By Ryan Cross
Department: Business
Keywords: Synthetic biology, start-ups, genetically recoded organisms, George Church

GRO Biosciences, a Boston-based synthetic biology start-up that spun out of Harvard University geneticist George Church’s lab, has received $2.1 million in seed funding from Digitalis Ventures and Innovation Endeavors. GRO uses genetically recoded bacteria, which incorporate additional amino acids beyond nature’s standard set of 20 molecules, to improve stability, potency, and other properties of therapeutic proteins. CEO Daniel Mandell says GRO is making antibodies and human growth hormone containing the nontraditional amino acid selenocysteine. The resulting diselenide bonds are more stable than the protein’s original disulfide bonds.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment